search
FDA
Trends
- 1E. coli outbreak tied to raw milk cheese sickens 13 across USโE. coli outbreak linked to raw milk cheese leads to 13 illnesses and eight hospitalizations across the US: FDA
US health regulators are investigating an E. coli outbreak linked to raw milk cheese that has caused 13 illnesses and eight hospitalizations across the country, according to the FDA. The announcement has raised renewed concerns about the safety of unpasteurized dairy products, with coverage highlighting the risks of raw milk consumption and calls for consumers to check products they may have purchased.
- 2
The FDA has announced a recall of raw milk cheese linked to an E. coli outbreak. Multiple US news outlets, including DC News Now, WTNH and NewsNation, are reporting the recall, which affects consumers who may have purchased the cheese. Health officials typically urge anyone with symptoms of E. coli infection, such as severe stomach cramps and diarrhea, to seek medical attention. Further details about the brand and affected states have not been provided in early reports.
- 3FDA links Ecuadorian black clams to hepatitis A outbreakโFDA warns black clams from Ecuador tied to hepatitis A outbreak, 30 hospitalized
The FDA has issued a warning that black clams imported from Ecuador are linked to a hepatitis A outbreak in the United States, with 30 people hospitalized so far. Consumers are being urged to avoid the shellfish as health officials investigate the source of contamination and track additional cases connected to the product.
- 4Thyroid medicine recall flagged as FDA's highest riskโThyroid medicine recall classified under FDA's highest risk level https:// blog.taursnd.haus/display/1a04 1b09-206a-b7ca
A thyroid medication has been recalled and the recall has been classified at the FDA's most serious risk level, meaning the agency considers the issue potentially life-threatening. The announcement is drawing attention as patients who rely on thyroid medicine are urged to check whether their supply is affected and follow FDA guidance on returning or replacing it.
- 5
Disc Medicine, a clinical-stage biotech company, is facing investor investigations following an FDA letter that raised concerns for shareholders. Law firms have reportedly begun looking into whether the company misled investors about its regulatory prospects. The development puts pressure on the stock and adds uncertainty to the company's drug approval timeline, drawing attention from biotech investors tracking FDA-related setbacks.